Modelling the relative cost-effectiveness of amelogenin in non-healing venous leg ulcers.
about
A systematic review of cost-effectiveness analyses of complex wound interventions reveals optimal treatments for specific wound typesSuccessful treatment of non-healing wounds with Xelma(R).Is it time to re-appraise the role of compression in non-healing venous leg ulcers?Clinical and cost-effectiveness of absorbent dressings in the treatment of highly exuding VLUs.Relative cost-effectiveness of a skin protectant in managing venous leg ulcers in the UK.Amelogenin Peptide Extract Increases Differentiation and Angiogenic and Local Factor Production and Inhibits Apoptosis in Human Osteoblasts
P2860
Modelling the relative cost-effectiveness of amelogenin in non-healing venous leg ulcers.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Modelling the relative cost-effectiveness of amelogenin in non-healing venous leg ulcers.
@en
Modelling the relative cost-effectiveness of amelogenin in non-healing venous leg ulcers.
@nl
type
label
Modelling the relative cost-effectiveness of amelogenin in non-healing venous leg ulcers.
@en
Modelling the relative cost-effectiveness of amelogenin in non-healing venous leg ulcers.
@nl
prefLabel
Modelling the relative cost-effectiveness of amelogenin in non-healing venous leg ulcers.
@en
Modelling the relative cost-effectiveness of amelogenin in non-healing venous leg ulcers.
@nl
P2093
P2860
P1476
Modelling the relative cost-effectiveness of amelogenin in non-healing venous leg ulcers.
@en
P2093
P2860
P304
216, 218-24
P356
10.12968/JOWC.2009.18.5.42176
P577
2009-05-01T00:00:00Z